CODX / Co-Diagnostics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SEC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2025 CO-DIAGNOSTICS, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2025 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employe

Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results

Exhibit 99.1 Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results Salt Lake City, Utah – August 14, 2025 – Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Results: ● Revenue of $0.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 10, 2025 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 28, 2025 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer i

Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results

Exhibit 99.1 Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results SALT LAKE CITY, May 8, 2025— Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Results: ● Revenue of $0.1 million, wh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2025 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer in

Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2025 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer

PLAN OF DISTRIBUTION

Exhibit 99.1 PLAN OF DISTRIBUTION We have entered into the Amended and Restated Equity Distribution Agreement dated April 25, 2025, with Piper Sandler and Clear Street LLC (“Clear Street” and together with Piper Sandler, the “Sales Agents”), as our sales agents, pursuant to which we may issue and sell from time to time shares of our common stock having an aggregate offering price of up to $17,111,

Amended and Restated Equity Distribution Agreement, dated as of April 25, 2025, by and among Co-Diagnostics, Inc., Piper Sandler & Co., and Clear Street LLC.

Exhibit 10.1 CO-DIAGNOSTICS, INC. AMENDED AND RESTATED EQUITY DISTRIBUTION AGREEMENT April 25, 2025 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 CLEAR STREET LLC 4 World Trade Center 150 Greenwich St., Floor 45 New York, New York 10007 Ladies and Gentlemen: Co-Diagnostics, Inc., a company organized under the laws of Utah (the “Company”), and Piper Sandler

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Amended and Restated Bylaws of Co-Diagnostics, Inc.

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CO-DIAGNOSTICS, INC. A Utah Corporation (as amended by the Board of Directors on November 4, 2024) CONTENTS Article I. Corporate Offices. 1 Section 1.1. Registered Office and Agent. 1 Section 1.2. Other Offices. 1 Article II. Meetings of Stockholders. 1 Section 2.1. Place of Meetings. 1 Section 2.2. Annual Meetings. 1 Section 2.3. Special Meetings. 1 Sect

Insider trading policies and procedures

Exhibit 19 Co-Dx Insider Trading Policies and Procedures 7.5 Insider Trading and Black Out Periods Applicable to All Company Personnel 7.5.1 General Prohibition on Insider Trading. You and any Related Person (as defined below) may not buy or sell securities of the Company while in possession of material nonpublic information or engage in any other action to take advantage of, or pass on to others,

Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results

Exhibit 99.1 Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results SALT LAKE CITY, March 27, 2025— Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Financial Results: ● Revenue

Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 27, 2025 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer

Subsidiaries of Registrant

Exhibit 21.1 List of Subsidiaries LIST OF SUBSIDIARIES Co-Diagnostics, Inc. (the “Company”) has the following direct and indirect subsidiaries: Subsidiary Name Jurisdiction of Formation Percentage of Ownership DNA Logix, Inc. Utah 100 % Idaho Molecular, Inc. Idaho 100 % Advanced Conceptions, Inc. Utah 100 %

Description of Registrant’s securities

EXHIBIT 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of our capital stock summarizes certain provisions of articles of incorporation, as amended (the “Articles of Incorporation”), our bylaws (the “Bylaws”), and applicable provisions of law. Such summaries do not purport to be complete and are sub

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 001-38148 CO-DIAGNOSTICS,

Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of a test component

Exhibit 99.1 Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of a test component Salt Lake City, Utah – February 21, 2025 – Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a uniqu

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2025 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Emplo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2025 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employ

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 29, 2024 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Com

Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results

Exhibit 99.1 Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results SALT LAKE CITY, November 7, 2024— Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Results: ● Revenue of $0.6 mi

Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2024 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.

Amendment to the Amended and Restated Bylaws

Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CO-DIAGNOSTICS, INC. A Utah Corporation (as adoptedamended by the Board of Directors on March 31, 2022November 4, 2024) CONTENTS Article I. Corporate Offices. 1 Section 1.1. Registered Office and Agent. 1 Section 1.2. Other Offices. 1 Article II. Meetings of Stockholders. 1 Section 2.1. Place of Meetings. 1 Section 2.2. Annual Meetings. 1 Section 2.3. Spe

Up to $17,111,650 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-270628 Prospectus Supplement (To Prospectus dated April 6, 2023) Up to $17,111,650 Common Stock We previously entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Piper Sandler & Co. (“Piper Sandler”), pursuant to which we may offer and sell shares of our common stock, $0.001 par value, having an aggregate of

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 29, 2024 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employe

Co-Diagnostics, Inc. Reports Second Quarter 2024 Financial Results

Exhibit 99.1 Co-Diagnostics, Inc. Reports Second Quarter 2024 Financial Results SALT LAKE CITY, August 8, 2024— Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Results: ● Revenue of $2.7 million

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SEC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.

Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2024 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs o

Exhibit 99.1 Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market Salt Lake City, Utah – June 14, 2024 – Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diag

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2024 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer

Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results

Exhibit 99.1 Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results SALT LAKE CITY, May 9, 2024— Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Dx,” or the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Results: ●

Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 15, 2024 CO-DIAGNOSTICS, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 15, 2024 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer

Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results

Exhibit 99.1 Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results SALT LAKE CITY, March 14, 2024— Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023. Full Year 2023 Financial Results: ● Revenue of $6.8 million, do

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 001-38148 CO-DIAGNOSTICS,

Co-Diagnostics, Inc. Clawback Policy

Exhibit 97 CO-DIAGNOSTICS, INC. INCENTIVE COMPENSATION RECOVERY POLICY 1. Introduction. The Board of Directors of Co-Diagnostics, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s compensation philosophy. The Board has therefore adopted th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2024 CO-DIAGNOSTICS, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2024 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer

Subsidiaries of Registrant

Exhibit 21.1 List of Subsidiaries LIST OF SUBSIDIARIES Co-Diagnostics, Inc. (the “Company”) has the following direct and indirect subsidiaries: Subsidiary Name Jurisdiction of Formation Percentage of Ownership DNA Logix, Inc. Utah 100 % Idaho Molecular, Inc. Idaho 100 % Advanced Conceptions, Inc. Utah 100 %

Description of Registrant’s securities

EXHIBIT 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of our capital stock summarizes certain provisions of articles of incorporation, as amended (the “Articles of Incorporation”), our bylaws (the “Bylaws”), and applicable provisions of law. Such summaries do not purport to be complete and are sub

CODX / Co-Diagnostics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Co-Diagnostics Inc Title of Class of Securities: Common Stock CUSIP Number: 189763105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.

Commercial Lease Agreement, dated September 18, 2023, between Ge Estate, LLC and Co-Diagnostics, Inc.

Exhibit 10.1 COMMERCIAL LEASE AGREEMENT This Commercial Lease Agreement (hereinafter, the “Lease”) is a legal and binding contract. Before signing, read the entire document, including the general printed provisions and any attachments. If you have any questions, consult your attorney before signing. This Lease is made and entered into as of the 18th day of September, 2023, by and between the follo

Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2023 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employ

Co-Diagnostics, Inc. Reports Third Quarter 2023 Financial Results Receives grant award from the Bill & Melinda Gates Foundation in the amount of $9.0M for the development of tuberculosis test on Co-Dx™ PCR platform.

Exhibit 99.1 Co-Diagnostics, Inc. Reports Third Quarter 2023 Financial Results Receives grant award from the Bill & Melinda Gates Foundation in the amount of $9.0M for the development of tuberculosis test on Co-Dx™ PCR platform. SALT LAKE CITY, November 9, 2023— Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular di

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 30, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 30, 2023 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SEC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.

Commercial Lease Agreement, dated June 1, 2023, between Ozone Biotech, LLC and Co-Diagnostics, Inc.

Exhibit 10.1 COMMERCIAL LEASE AGREEMENT This Commercial Lease Agreement (hereinafter, the “Lease”) is a legal and binding contract. Before signing, read the entire document, including the general printed provisions and any attachments. If you have any questions, consult your attorney and/or accountant before signing. This Lease is made and entered into effective as of the 1st day of June, 2023 (th

Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2023 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employe

Co-Diagnostics, Inc. Reports Second Quarter 2023 Financial Results Co-Dx receives grant awards from the Bill & Melinda Gates Foundation; NIH RADx® Tech to develop tests on our new Co-Dx PCR Home™ platform

Exhibit 99.1 Co-Diagnostics, Inc. Reports Second Quarter 2023 Financial Results Co-Dx receives grant awards from the Bill & Melinda Gates Foundation; NIH RADx® Tech to develop tests on our new Co-Dx PCR Home™ platform SALT LAKE CITY, August 10, 2023— Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tes

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Co-Diagnostics, Inc. Change in Control Plan

Exhibit 10.1 co-diagnostics, inc. CHANGE-IN-CONTROL Severance Plan CO-DIAGNOSTICS, INC. CHANGE-IN-CONTROL SEVERANCE PLAN TABLE OF CONTENTS SECTION 1 - INTRODUCTION 2 SECTION 2 - DEFINITIONS 2 SECTION 3 - ELIGIBILITY FOR SEVERANCE 4 SECTION 4 - AMOUNT OF SEVERANCE PAY AND OTHER BENEFITS 4 SECTION 5 - WHEN SEVERANCE PAY WILL BE PAID 5 SECTION 6 - MISCELLANEOUS PROVISIONS 5 SECTION 7 - ADMINISTRATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2023 CO-DIAGNOSTICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2023 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2023 CO-DIAGNOSTICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2023 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.

Co-Diagnostics, Inc. Reports First Quarter 2023 Financial Results Clinical trials for Co-Dx PCR Home™ platform remain on track; Solid cash position and grant funding support long-term strategy

Exhibit 99.1 Co-Diagnostics, Inc. Reports First Quarter 2023 Financial Results Clinical trials for Co-Dx PCR Home™ platform remain on track; Solid cash position and grant funding support long-term strategy SALT LAKE CITY, May 11, 2023— Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced t

Letter of Haynie & Company Regarding Change in Certifying Accountant.

Exhibit 16.1 April 5, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated April 5, 2023, of Co-Diagnostics, Inc. and are in agreement with the statements contained in the second and third paragraphs therein. We have no basis to agree or disagree with other statements of the registrant contained therein. /s/

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2023 CO-DIAGNOSTICS, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2023 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer

CO-DIAGNOSTICS, INC.

CO-DIAGNOSTICS, INC. April 4, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Co-Diagnostics, Inc.—Registration Statement on Form S-3 (File No. 333-270628) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of

Form of Indenture

EXHIBIT 4.1 CO-DIAGNOSTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities Table of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Section 2

Common Stock Purchase Warrant issued to Coltrin & Associates dated October 31, 2019

Exhibit 4.9 WARRANT THIS WARRANT AND ANY SHARES ACQUIRED UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF EXCEPT (I) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT, (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT OR (III) AN OPIN

Common Stock Purchase Warrant issued to Coltrin & Associates dated February 6, 2020

Exhibit 4.11 WARRANT THIS WARRANT AND ANY SHARES ACQUIRED UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF EXCEPT (I) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT, (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT OR (III) AN OPI

As filed with the Securities and Exchange Commission on March 16, 2023

As filed with the Securities and Exchange Commission on March 16, 2023 Registration No.

Co-Diagnostics, Inc. Reports Full Year 2022 Financial Results Full-year Results Impacted by Lower Demand for COVID-19 Testing Announced Initiation of Clinical Evaluations for Co-Dx PCR Home™ Platform

Exhibit 99.1 Co-Diagnostics, Inc. Reports Full Year 2022 Financial Results Full-year Results Impacted by Lower Demand for COVID-19 Testing Announced Initiation of Clinical Evaluations for Co-Dx PCR Home™ Platform SALT LAKE CITY, March 16, 2023— Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 001-38148 CO-DIAGNOSTICS,

Amendment dated July 31, 2020 to Common Stock Purchase Warrant issued to Coltrin & Associates dated October 31, 2019

Exhibit 4.12 AMENDMENT TO WARRANT This Amendment, dated as of July 31, 2020 (this “Amendment”), made and entered into by and between CO-DIAGNOSTICS, INC., a Utah corporation (the “Company”), and COLTRIN & ASSOCIATES, INC. (the “Holder”), amends the Warrant dated October 31, 2019 (the “Warrant”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the War

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 CO-DIAGNOSTICS, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer

Subsidiaries of Registrant

Exhibit 21.1 List of Subsidiaries LIST OF SUBSIDIARIES Co-Diagnostics, Inc. (the “Company”) has the following direct and indirect subsidiaries: Subsidiary Name Jurisdiction of Formation Percentage of Ownership DNA Logix, Inc. Utah 100 % Idaho Molecular, Inc. Idaho 100 % Advanced Conceptions, Inc. Utah 100 %

Common Stock Purchase Warrant issued to Coltrin & Associates dated February 6, 2020

Exhibit 4.10 WARRANT THIS WARRANT AND ANY SHARES ACQUIRED UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF EXCEPT (I) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT, (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT OR (III) AN OPI

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Co-Diagnostics, Inc.

Equity Distribution Agreement, dated as of March 16, 2023 by and between the Registrant and Piper Sandler & Co.

Exhibit 1.2 CO-DIAGNOSTICS, INC. EQUITY DISTRIBUTION AGREEMENT March 16, 2023 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Co-Diagnostics, Inc., a company organized under the laws of Utah (the “Company”), proposes to issue and sell from time to time through Piper Sandler & Co.

CODX / Co-Diagnostics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0609-codiagnosticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Co-Diagnostics Inc. Title of Class of Securities: Common Stock CUSIP Number: 189763105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designat

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Co-Diagnostics, Inc.

As filed with the Securities and Exchange Commission on January 23, 2023

As filed with the Securities and Exchange Commission on January 23, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.

Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2022 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Emplo

Co-Diagnostics, Inc. Reports Third Quarter 2022 Financial Results Nearing commencement of clinical evaluations for the Co-Dx PCR Home platform COVID-19 test volumes continue to impact third quarter results

Exhibit 99.1 Co-Diagnostics, Inc. Reports Third Quarter 2022 Financial Results Nearing commencement of clinical evaluations for the Co-Dx PCR Home platform COVID-19 test volumes continue to impact third quarter results SALT LAKE CITY, November 10, 2022— Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 31, 2022 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employe

Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2022 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employe

Co-Diagnostics, Inc. Reports Second Quarter 2022 Financial Results Second quarter results impacted by volume declines; Further progress on the development of the Co-Dx PCR Home platform

Exhibit 99.1 Co-Diagnostics, Inc. Reports Second Quarter 2022 Financial Results Second quarter results impacted by volume declines; Further progress on the development of the Co-Dx PCR Home platform SALT LAKE CITY, August 11, 2022? Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SEC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Amendment to Agreement and Plan of Merger by and among Co-Diagnostics, Inc., Advanced Conceptions, Inc., and Richard Abbott, as Company Representative

Exhibit 2.1 AMENDMENT TO AGREEMENT AND PLAN OF MERGER This AMENDMENT TO Agreement AND PLAN OF MERGER (this ?Amendment?), dated as of June 10, 2022, is entered into by and among Co-Diagnostics, Inc., a Utah corporation (?Parent?), Advanced Conceptions, Inc., a Utah corporation (?Surviving Co.?), and Richard Abbott, as Company Representative (?Representative?). RECITALS A. Parent, Surviving Co., ACI

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 CO-DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Utah 001-38148 46-2609363 (State or other jurisdiction of incorporation) (Commission File Num

Amendment to Agreement and Plan of Merger by and among Co-Diagnostics, Inc., Idaho Molecular, Inc., and Kirk Ririe, as Company Representative

Exhibit 2.2 AMENDMENT TO AGREEMENT AND PLAN OF MERGER This AMENDMENT TO Agreement AND PLAN OF MERGER (this ?Amendment?), dated as of June 10, 2022, is entered into by and among Co-Diagnostics, Inc., a Utah corporation (?Parent?), Idaho Molecular Inc., an Idaho corporation (?Surviving Co.?), and Kirk Ririe, as Company Representative (?Representative?). RECITALS A. Parent, Surviving Co., Idmo Acquis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.

Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2022 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer i

Co-Diagnostics Reports Solid First Quarter 2022 Financial Results Strong results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34

Exhibit 99.1 Co-Diagnostics Reports Solid First Quarter 2022 Financial Results Strong results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34 SALT LAKE CITY, May 12, 2022? Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 CO-DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Utah 001-38148 46-2609363 (State or other jurisdiction of incorporation) (Commission File Nu

Amended and Restated Bylaws of Co-Diagnostics, Inc.

Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CO-DIAGNOSTICS, INC. A Utah Corporation (as adopted by the Board of Directors on March 31, 2022) Contents Article I. Corporate Offices. 1 Section 1.1. Registered Office and Agent. 1 Section 1.2. Other Offices. 1 Article II. Meetings of Stockholders. 1 Section 2.1. Place of Meetings. 1 Section 2.2. Annual Meetings. 1 Section 2.3. Special Meetings. 1 Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 001-38148 CO-DIAGNOSTICS,

Warrant Agreement between Co-Diagnostics, Inc and VStock Transfer, LLC. Dated December 31, 2021 (ACI Warrant)

Exhibit 10.6 COMPANY WARRANT AGREEMENT THIS WARRANT AGREEMENT (this ?Agreement?), dated as of December 31, 2021, is entered into by and between Co-Diagnostics, Inc., a Utah corporation (?Parent? or the ?Company?), and VStock Transfer, LLC (the ?Warrant Agent?). WHEREAS, Parent consummated a merger (the ?Merger?) of its wholly-owned subsidiary, ACI Acquisition Corp. (?Subco?), with and into Advance

Co-Diagnostics Reports Full Year 2021 Financial Results Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY’22

Exhibit 99.1 Co-Diagnostics Reports Full Year 2021 Financial Results Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY?22 SALT LAKE CITY, March 24, 2022?Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial

Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2022 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer

Description of Registrant’s securities

EXHIBIT 4.1 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of our capital stock summarizes certain provisions of articles of incorporation, as amended (the ?Articles of Incorporation?), our bylaws (the ?Bylaws?), and applicable provisions of law. Such summaries do not purport to be complete and are sub

Amendment #1 to Lease

Exhibit 10.9.1 AMENDMENT #1 TO LEASE That certain Lease with a Commencement Date of February 1, 2018 between YESCO Properties, LLC, a Utah Limited Liability Company (?Landlord?) and Co-Diagnostics, Inc., a Utah Corporation (?Tenant?) (the ?Lease?) as amended by that First Lease Addendum dated June 5, 2018, is by this Amendment #1 to the Lease (this ?Amendment?) modified. This Amendment is dated Ma

Warrant Agreement between Co-Diagnostics, Inc and VStock Transfer, LLC. Dated December 31, 2021 (IDMO Warrant)

Exhibit 10.7 COMPANY WARRANT AGREEMENT THIS WARRANT AGREEMENT (this ?Agreement?), dated as of December 31, 2021, is entered into by and between Co-Diagnostics, Inc., a Utah corporation (?Parent? or the ?Company?), and VStock Transfer, LLC (the ?Warrant Agent?). WHEREAS, Parent consummated a merger (the ?Merger?) of its wholly-owned subsidiary, IDMO Acquisition Corporation, Inc. (?Subco?), with and

Lease Agreement 2401 Foothill Drive

Exhibit 10.9 LEASE AGREEMENT 2401 FOOTHILL DRIVE THIS LEASE AGREEMENT (this ?Lease?) is entered into as of the day of June, 2018, between YESCO Properties, LLC, a Utah company (?Landlord?), whose address is 2401 Foothill Dr., SLC, UT 84109, and Co-Diagnostics, a Utah company (?Tenant?), whose address is 2401 Foothill Drive, SLC, UT 84109. Landlord and Tenant agree as follows: 1. Definitions. As us

Articles of Amendment

Exhibit 3.1.3 ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF CO-DIAGNOSTICS, INC. Pursuant to and in accordance with the provisions of Section 16-10a-1006 of the Utah Revised Business Corporation Act, as amended (the ?Act??), the undersigned, Co-Diagnostics, Inc. (the ?Corporation?) hereby declares and certifies the following Articles of Amendment to its Articles of Incorporation. 1. Th

Subsidiaries of Registrant

Exhibit 21.1 List of Subsidiaries LIST OF SUBSIDIARIES Co-Diagnostics, Inc. (the ?Company?) has the following direct and indirect subsidiaries: Subsidiary Name Jurisdiction of Formation Percentage of Ownership DNA Logix, Inc. Utah 100 % Idaho Molecular, Inc. Idaho 100 % Advanced Conceptions, Inc. Utah 100 %

Amendment #2 to Lease

Exhibit 10.9.2 AMENDMENT #2 TO LEASE That certain Lease with a Commencement Date of February 1, 2018 between YESCO Properties; LLC, a Utah Limited Liability Company (?Landlord?) and Co-Diagnostics, Inc., a Utah Corporation (?Tenant?) (the ?Lease?) as amended by that First Lease Addendum dated June 5, 2018, and Amendment to Lease #1 dated March 26, 2020 (Amendment #1) is by this Amendment #2 to the

Co-Diagnostics, Inc. Announces Authorization of $30 Million Share Repurchase Program

Exhibit 99.1 Co-Diagnostics, Inc. Announces Authorization of $30 Million Share Repurchase Program Salt Lake City, Utah ? March 15, 2022 ? Co-Diagnostics, Inc. (Nasdaq: CODX) (the ?Company?), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Board of Directors has authorized a share repurchase program that wo

Regulation FD Disclosure, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 CO-DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Utah 001-38148 46-2609363 (State or other jurisdiction of incorporation) (Commission File Nu

CODX / Co-Diagnostics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Co-Diagnostics Inc. Title of Class of Securities: Common Stock CUSIP Number: 189763105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒

Agreement and Plan of Merger by and between Co-Diagnostics, Inc, IDMO Acquisition Corp., Idaho Molecular Inc., and Company Representative dated as of December 21, 2021.

Exhibit 2.1 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT 2.1 BECAUSE IT IS BOTH NOT MATERIAL AND is the type of information the issuer both customarily and actually treats as private and confidentiaL. [***] DENOTES INFORMATION THAT HAS BEEN OMITTED. AGREEMENT AND PLAN OF MERGER among CO-DIAGNOSTICS, INC., IDMO ACQUISITION CORP., IDAHO MOLECULAR INC. and COMPANY REPRESENTATIVE Dated Dece

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2021 CO-DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Utah 001-38148 46-2609363 (State or other jurisdiction of incorporation) (Commission File

Agreement and Plan of Merger by and between Co-Diagnostics, Inc, ACI Acquisition Corp., Advanced Conceptions, Inc., and Company Representative dated as of December 21, 2021

EX-2.2 3 ex2-2.htm Exhibit 2.2 CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT 2.2 BECAUSE IT IS BOTH NOT MATERIAL AND is the type of information the issuer both customarily and actually treats as private and confidentiaL. [***] DENOTES INFORMATION THAT HAS BEEN OMITTED. AGREEMENT AND PLAN OF MERGER among CO-DIAGNOSTICS, INC., ACI ACQUISITION CORP., ADVANCED CONCEPTIONS, INC. and COMPANY R

Co-Diagnostics, Inc. Signs Agreement to Acquire all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform Definitive merger agreements provide the Company with all existing and future assets, future product iterations, and intell

Exhibit 99.1 Co-Diagnostics, Inc. Signs Agreement to Acquire all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform Definitive merger agreements provide the Company with all existing and future assets, future product iterations, and intellectual property rights of the platform, creating a fully integrated product line and streamlining commercialization Salt Lake City, Utah

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.

Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2021 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Emplo

Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results Solid quarterly results highlighted by record revenue of $30.1 million, pre-tax income of $13.6 million and fully diluted EPS of $0.38

Exhibit 99.1 Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results Solid quarterly results highlighted by record revenue of $30.1 million, pre-tax income of $13.6 million and fully diluted EPS of $0.38 SALT LAKE CITY, November 11, 2021?Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular d

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SEC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.

Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2021 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employe

Co-Diagnostics Reports Strong Second Quarter 2021 Financial Results Solid quarterly results highlighted by revenue of $27.4 million, pre-tax income of $11.9 million and diluted EPS of $0.33

Exhibit 99.1 Co-Diagnostics Reports Strong Second Quarter 2021 Financial Results Solid quarterly results highlighted by revenue of $27.4 million, pre-tax income of $11.9 million and diluted EPS of $0.33 SALT LAKE CITY, August 12, 2021?Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced to

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2021 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 001-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employ

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 8, 2021 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Co-Diagnostics Reports First Quarter 2021 Financial Results Strong quarterly results highlighted by revenue of $20.0 million, pre-tax income of $9.9 million and diluted EPS of $0.26

Exhibit 99.1 Co-Diagnostics Reports First Quarter 2021 Financial Results Strong quarterly results highlighted by revenue of $20.0 million, pre-tax income of $9.9 million and diluted EPS of $0.26 SALT LAKE CITY, May 13, 2021?Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financi

Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2021 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 [ ] TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.

Co-Diagnostics Reports Fourth-Quarter and Full-Year 2020 Financial Results Record quarterly results highlighted by revenue of $27.1 million and pre-tax income of $15.8 million

Exhibit 99.1 Co-Diagnostics Reports Fourth-Quarter and Full-Year 2020 Financial Results Record quarterly results highlighted by revenue of $27.1 million and pre-tax income of $15.8 million SALT LAKE CITY, UTAH; March 25, 2021—Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today finan

Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 25, 2021 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer

Description of Registrant’s securities

EXHIBIT 4.1 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of March 24, 2021, Co-Diagnostics, Inc. (?Co-Diagnostics? or the ?Company?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): common stock, par value $0.001 per share (?Common Stock?). The

Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Form 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 001-38148 CO-DIAGNOST

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 22, 2021 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Emplo

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Co-Diagnostics Inc. Title of Class of Securities: Common Stock CUSIP Number: 189763105 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rul

Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2021 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employe

Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products

Exhibit 99.1 Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products Salt Lake City, Utah – January 6, 2021 – Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, based on its preliminary internal finan

Submission of Matters to a Vote of Security Holders -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 CO-DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of incorporation) (Commission File N

Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan

Exhibit 4.1 CO-DIAGNOSTICS, INC. 2015 LONG TERM INCENTIVE PLAN Amended and Restated as of November 20, 2020 1. GENERAL 1. Purpose. The Co-Diagnostics, Inc. 2015 Long Term Incentive Plan (the “Plan”) has been established by Co-Diagnostics, Inc. (the “Company”) to: (1) attract and retain key executive and managerial employees of the Company; (2) attract and retain directors, independent contractors,

-

As filed with the Securities and Exchange Commission on November 20, 2020 Registration No.

Co-Diagnostics, Inc. Announces Q3 2020 Financial Results Including YTD Net Income per Common Share of $1.07 Company also announces receipt of CE markings for both Logix Smart ABC and SARS-CoV-2 2-gene tests

EXHIBIT 99.1 Co-Diagnostics, Inc. Announces Q3 2020 Financial Results Including YTD Net Income per Common Share of $1.07 Company also announces receipt of CE markings for both Logix Smart ABC and SARS-CoV-2 2-gene tests Salt Lake City, Utah – November 16, 2020 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular di

Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 16, 2020 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Emplo

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 OR [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No.

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A (Amendment No.

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Regulation FD Disclosure, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2020 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employ

-

November 2, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F.

Co-Diagnostics, Inc. to Amend Q2 2020 Form 10-Q to Show $0.51 Net Income per Share

Exhibit 99.1 Co-Diagnostics, Inc. to Amend Q2 2020 Form 10-Q to Show $0.51 Net Income per Share Salt Lake City, Utah – November 2, 2020 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that following the discovery of an incorrectly recorded expense in the period ending June 30,

Letter, dated November 2, 2020, from Haynie & Company to the U.S. Securities and Exchange Commission

EXHIBIT 7.1 November 2, 2020 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Co-Diagnostics, Inc. (the “Company”) Ladies and Gentlemen: We have read the Company’s disclosure set forth in Item 4.02, “Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review” of the Company’s Current Report on Form 8-K, and are in ag

-

As filed with the Securities and Exchange Commission on October 23, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CO-DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Utah 46-2609396 (State or other jurisdiction of incorporation or organization) (I.R.S. Empl

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 OR [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2020 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of incorporation or organizati

Co-Diagnostics, Inc. Releases Prepared Remarks for First Quarter 2020 Conference Call

Exhibit 99.2 Co-Diagnostics, Inc. Releases Prepared Remarks for First Quarter 2020 Conference Call Salt Lake City, Utah – May 14, 2020 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, releases the prepared remarks for the Q1 2020 conference call scheduled for May 14, 2020. Due to overwhelming

Co-Diagnostics, Inc. Announces Q1 2020 Results and Provides Mid-Second Quarter Update Company reports robust sales of COVID-19 tests as Co-Diagnostics generates net profit through middle of second quarter

Exhibit 99.1 Co-Diagnostics, Inc. Announces Q1 2020 Results and Provides Mid-Second Quarter Update Company reports robust sales of COVID-19 tests as Co-Diagnostics generates net profit through middle of second quarter Salt Lake City, Utah – May 14, 2020 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnosti

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2020 OR [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No.

CODX / Co-Diagnostics Inc S-8 - -

As filed with the Securities and Exchange Commission on April 13, 2020 Registration No.

CODX / Co-Diagnostics Inc 10-K - Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Form 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 001-38148 CO-DIAGNOST

Code of Ethics for Senior Financial Officers

EX-14.1 2 ex14-1.htm Exhibit 14.1 Co-Diagnostics, Inc. Code of Ethics for Senior Financial Officers Co-Diagnostics, Inc. (the “Corporation”) believes that senior financial officers, including, but not limited to the Corporation’s chief executive officer, principal financial officer, controller or principal accounting officer, and persons who perform similar functions (collectively, the “Senior Fin

CO-DIAGNOSTICS, INC. 470,000 Shares of Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-226835 PROSPECTUS SUPPLEMENT (To Prospectus dated August 14, 2018) CO-DIAGNOSTICS, INC. 470,000 Shares of Common Stock We are offering an aggregate of 470,000 shares of common stock, $0.001 par value per share to institutional accredited investors pursuant to this prospectus supplement and the accompanying base prospectus. Our common stock is t

Co-Diagnostics Announces $4.2 Million Registered Direct Offering Priced At-the-Market

Exhibit 99.1 Co-Diagnostics Announces $4.2 Million Registered Direct Offering Priced At-the-Market Salt Lake City, Utah – February 27, 2020 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into definitive agreements with institutional investors for the purch

Form of Securities Purchase Agreement, dated February 27, 2020

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 27, 2020, between Co-Diagnostics, Inc., a Utah corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set

Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 27, 2020 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of incorporation or organ

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2020 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of incorporation or organ

Co-Diagnostics Announces Closing of $10.2 Million Registered Direct Offering Priced At-the-Market

Exhibit 99.1 Co-Diagnostics Announces Closing of $10.2 Million Registered Direct Offering Priced At-the-Market Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the closing of its previously announced registered direct offering of 3,324,676 shares of its common stock at a purchase

CO-DIAGNOSTICS, INC. 3,324,676 Shares of Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-226835 PROSPECTUS SUPPLEMENT (To Prospectus dated August 14, 2018) CO-DIAGNOSTICS, INC. 3,324,676 Shares of Common Stock We are offering an aggregate of 3,324,676 shares of common stock, $0.001 par value per share to institutional accredited investors pursuant to this prospectus supplement and the accompanying base prospectus. Our common stock

Co-Diagnostics Announces $10.2 Million Registered Direct Offering Priced At-the-Market

Exhibit 99.1 Co-Diagnostics Announces $10.2 Million Registered Direct Offering Priced At-the-Market Salt Lake City, Utah – February 11, 2020 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into definitive agreements with institutional investors for the purc

Form of Securities Purchase Agreement, dated February 10, 2020.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 10, 2020, between Co-Diagnostics, Inc., a Utah corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set

Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2020 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of incorporation or organ

CODX / Co-Diagnostics Inc / CVI Investments, Inc. - SC 13G/A Passive Investment

CUSIP No: 189763105 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Co-Diagnostics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 189763105 (CUSIP Number)

CO-DIAGNOSTICS, INC. 3,448,278 Shares of Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-226835 PROSPECTUS SUPPLEMENT (To Prospectus dated August 14, 2018) CO-DIAGNOSTICS, INC. 3,448,278 Shares of Common Stock We are offering an aggregate of 3,448,278 shares of common stock, $0.001 par value per share to institutional accredited investors pursuant to this prospectus supplement and the accompanying base prospectus. Our common stock

Co-Diagnostics Announces $5.0 Million Registered Direct Offering Priced At-the-Market

Exhibit 99.1 Co-Diagnostics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Salt Lake City, Utah – January 24, 2020 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into definitive agreements with institutional investors for the purcha

Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 23, 2020 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of incorporation or organi

Form of Securities Purchase Agreement, dated January 23, 2020.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January [], 2020, between Co-Diagnostics, Inc., a Utah corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set

CODX / Co-Diagnostics Inc 10-Q - Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 OR [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 30, 2019 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of incorporation or organiz

CODX / Co-Diagnostics Inc 10-Q - Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 OR [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No.

CODX / Co-Diagnostics Inc DEF 14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 5, 2019 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of incorporation or organizati

Co-Diagnostics, Inc. Announces New Additions to Board of Directors

EXHIBIT 99.1 Co-Diagnostics, Inc. Announces New Additions to Board of Directors Salt Lake City, Utah – June 27, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dr. Eugene Durenard and Mr. Ted Murphy have joined the Board of Directors of Co-Diagnostics, and will serve

Financial Statements and Exhibits, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 20, 2019 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer

CODX / Co-Diagnostics Inc 10-Q Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 OR [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No.

CODX / Co-Diagnostics Inc / America 2030 Capital Ltd. - CODX SCH13G AMERICA 2030 LTD 05/09/19 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.   )* Co-Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 189763105 (CUSIP Number) December 6, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc

CODX / Co-Diagnostics Inc / America 2030 Capital, Llc - CODX AMERICA2030 SC13G 02/19/19 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.   )* Co-Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 189763105 (CUSIP Number) April 27, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2019 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer

Form of Second Amendment Agreement

CODX / Co-Diagnostics Inc (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Form 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 0-13316 CO-DIAGNOSTIC

Code of Ethics of the Company

Co-Diagnostics, Inc. Code of Ethics for Senior Financial Officers Co-Diagnostics, Inc. (the “Corporation”) believes that senior financial officers, including, but not limited to the Corporation’s chief executive officer, principal financial officer, controller or principal accounting officer, and persons who perform similar functions (collectively, the “Senior Financial Officers”), hold an importa

Co-Diagnostics, Inc. Regains Compliance with NASDAQ Listing Standards

Co-Diagnostics, Inc. Regains Compliance with NASDAQ Listing Standards Salt Lake City, Utah – Feb 22, 2019 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has received written notice from the Nasdaq Stock Market (“Nasdaq”) Listing Qualifications Staff on February 19, 20

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 19, 2019 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of incorporation or organ

CODX / Co-Diagnostics Inc / CVI Investments, Inc. - SC 13G Passive Investment

CUSIP No: 189763105 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Co-Diagnostics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 189763105 (CUSIP Number)

Co-Diagnostics, Inc. Announces Closing of $5.5 Million Registered Direct Offering

Co-Diagnostics, Inc. Announces Closing of $5.5 Million Registered Direct Offering Salt Lake City, Utah – February 4, 2019 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the closing of its previously announced offering. In a registered direct offering, Co-Diagnostics issued an

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2019 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of incorporation or organi

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 30, 2019 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of incorporation or organi

Co-Diagnostics Announces $5.5 Million Registered Direct Offering

Co-Diagnostics Announces $5.5 Million Registered Direct Offering Salt Lake City, Utah – January 31, 2019 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into definitive agreements with institutional investors for the purchase of 3,925,716 shares of its comm

Form of Securities Purchase Agreement, dated January 31, 2019, for the Common Stock.

SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 31, 2019, between Co-Diagnostics, Inc.

Form of Securities Purchase Agreement, dated January 30, 2019, for the Preferred Stock.

SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 30, 2019, by and between Co-Diagnostics, Inc.

Co-Diagnostics, Inc. Announces Elimination of Debt, Additional Capital Infusion

Co-Diagnostics, Inc. Announces Elimination of Debt, Additional Capital Infusion SALT LAKE CITY—(BUSINESS WIRE)—Jan 30, 2019—Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the sale of $3 million of preferred shares, convertible to common stock at a fixed price of $1.20 per share

Certificate of Designation of the Series A Preferred Stock.

EXHIBIT A CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES A CONVERTIBLE PREFERRED STOCK OF CO-DIAGNOSTICS, INC.

CO-DIAGNOSTICS, INC. 3,925,716 Shares of Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-226835 PROSPECTUS SUPPLEMENT (To Prospectus dated August 14, 2018) CO-DIAGNOSTICS, INC. 3,925,716 Shares of Common Stock We are offering an aggregate of 3,925,716 shares of common stock, $0.001 par value per share to institutional accredited investors pursuant to this prospectus supplement and the accompanying base prospectus. Our common stock

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 18, 2019 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of incorporation or organi

CODX / Co-Diagnostics Inc / Bentley Rothschild Financial, Llc - SCHEDULE 13G 01/17/19 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.   )* Co-Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 189763105 (CUSIP Number) July 18, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched

Articles of Amendment to Articles of Incorporation

FORM OF ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION OF CO-DIAGNOSTICS, INC.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 27, 2018 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of incorporation or organ

CODX / Co-Diagnostics Inc DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P

CODX / Co-Diagnostics Inc PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P

CODX / Co-Diagnostics Inc 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2018 OR [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No.

Co-Diagnostics, Inc. and LGC, Biosearch Technologies Sign License Agreement for CoPrimer Technology Co-Diagnostics agrees to license CoPrimers™ for use in agricultural applications

Co-Diagnostics, Inc. and LGC, Biosearch Technologies Sign License Agreement for CoPrimer Technology Co-Diagnostics agrees to license CoPrimers™ for use in agricultural applications Salt Lake City, Utah – October 30, 2018 - Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, and LGC, Biosearch Te

Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2018 CO-DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of incorporation) (Commission File Nu

CODX / Co-Diagnostics Inc CORRESP

CO-DIAGNOSTICS, INC. 2401 S. Foothill Drive Salt Lake City, Utah 84109 (801) 438-1036 September 5, 2018 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 RE: Co-Diagnostics, Inc. Registration Statement on Form S-3 (File No. 333-226835) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the

CODX / Co-Diagnostics Inc S-3

As filed with the Securities and Exchange Commission on August 14, 2018 Registration No.

Subsidiaries of Registrant*

EXHIBIT 21.1 LIST OF SUBSIDIARIES Co-Diagnostics Inc. (the “Company”) has the following direct and indirect subsidiaries: Subsidiary Name Jurisdiction of Formation Percentage of Ownership DNA Logix, Inc. Utah 100 %

CODX / Co-Diagnostics Inc 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2018 OR [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No.

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2018 CO-DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of incorporation) (Commission File Numb

9% Promissory Note, dated August 3, 2018, between Co-Diagnostics, Inc. and Robert Salna for $2,000,000

THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES.

CODX / Co-Diagnostics Inc 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 OR [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No.

CODX / Co-Diagnostics Inc FORM 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number 1-38148 CO-DIAGNOSTICS, I

CODX / Co-Diagnostics Inc FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2017 OR ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No.

CODX / Co-Diagnostics Inc FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2017 OR ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No.

Co-Diagnostics, Inc.

PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-217542 Co-Diagnostics, Inc. 741,753 Shares of Common Stock Shares of Common Stock An aggregate of up to 741,753 shares of our common stock, consisting of (i) 423,859 shares of our common stock issuable upon conversion of notes held by selling shareholders and (ii) 317,894 shares of our common stock issuable upon exercise of outstandi

Co-Diagnostics, Inc.

PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-217542 Co-Diagnostics, Inc. 1,178,532 Shares of Common Stock This is an initial public offering of common stock of Co-Diagnostics, Inc. The initial public offering price is $6.00 per share. Prior to this offering, there has been no public market for our common stock. Our common stock is listed on the NASDAQ Capital Market under the s

Underwriting Agreement dated July 12, 2017.

EXHIBIT 1.1 UNDERWRITING AGREEMENT among CO-DIAGNOSTICS, INC. and WALLACHBETH Capital, LLC and NETWORK 1 FINANCIAL SECURITIES, INC., as Representatives of the Several Underwriters 1 CO-DIAGNOSTICS, INC. UNDERWRITING AGREEMENT New York, New York July 12, 2017 WallachBeth Capital, LLC Network 1 Financial Securities, Inc. As Representatives of the several Underwriters named on Schedule 1 attached her

Co-Diagnostics, Inc. Announces Pricing of Initial Public Offering

EXHIBIT 99.1 Co-Diagnostics, Inc. Announces Pricing of Initial Public Offering Salt Lake City, UT ? July 12, 2017 ? Co-Diagnostics, Inc. (NASDAQ: CODX) (?Co-Diagnostics? or the ?Company?), a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests, announced today that its initial public offering of 1,178,532 shares of common stock has

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 12, 2017 Co-Diagnostics, Inc. (Exact name of registrant as specified in its charter) Utah 333-217542 46-2609396 (State or Other Jurisdiction of Incorporation or Organization) (Co

-

July 11, 2017 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Re: Co-Diagnostics, Inc. Registration Statement on Form S-1 File No. 333-217542 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned hereby join in the request of Co-Diagnostics, Inc. that the effective date of the above-captioned

Form 8-A

8-A12B 1 axdx8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 CO-DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Utah 46-2609396 (State of Incorporation or Organization) (I.R.S. Employer Identification

Co-Diagnostics, Inc. 8160 S. Highland Drive Salt Lake City, Utah 84124

Co-Diagnostics, Inc. 8160 S. Highland Drive Salt Lake City, Utah 84124 July 11, 2017 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Amanda Ravitz, Assistant Director Re: Co-Diagnostics, Inc. Registration Statement on Form S-1 (Registration No. 333-217542) Ladies and Gentlemen: In accord

Form of Second Amendment Agreement

EXHIBIT 10.7.2 SECOND AMENDMENT AGREEMENT This SECOND AMENDMENT AGREEMENT, dated as of July 10, 2017 (the ?Second Amendment?), is made by and among CO-DIAGNOSTICS, INC., a Utah corporation (and together with all of its current and future, direct and/or indirect, wholly owned and/or partially owned Subsidiaries, collectively, the ?Company?) and each purchaser identified on the signature pages heret

As filed with the Securities and Exchange Commission on July 10, 2017

As filed with the Securities and Exchange Commission on July 10, 2017 Registration No.

-

Co-Diagnostics, Inc. 8160 S. Highland Drive Salt Lake City, Utah 84124 June 28, 2017 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Amanda Ravitz, Assistant Director Re: Co-Diagnostics, Inc. Registration Statement on Form S-1 (Registration No. 333-217542) Ladies and Gentlemen: In accord

Form of Amendment Agreement (6)

EXHIBIT 10.7.1 AMENDMENT AGREEMENT This AMENDMENT AGREEMENT, dated as of June 9, 2017 (the ?Amendment?), is made by and among CO-DIAGNOSTICS, INC., a Utah corporation (and together with all of its current and future, direct and/or indirect, wholly owned and/or partially owned Subsidiaries, collectively, the ?Company?) and each purchaser identified on the signature pages hereto (the ?Purchasers? an

- FORM S-1/A

As filed with the Securities and Exchange Commission on June 2 3 , 2017 Registration No.

Underwriting Agreement (5)

EXHIBIT 1.1 UNDERWRITING AGREEMENT among CO-DIAGNOSTICS, INC. and WALLACHBETH Capital, LLC and NETWORK 1 FINANCIAL SECURITIES, INC., as Representatives of the Several Underwriters 1 CO-DIAGNOSTICS, INC. UNDERWRITING AGREEMENT New York, New York [?], 2017 WallachBeth Capital, LLC Network 1 Financial Securities, Inc. As Representatives of the several Underwriters named on Schedule 1 attached hereto

CO-DIAGNOSTICS, INC. FREE WRITING PROSPECTUS

Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated June 9, 2017 Relating to Preliminary Prospectus dated June 9, 2017 Registration No.

June 9, 2017

June 9, 2017 Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, DC 20549 Attn: Amanda Ravitz Re: Co-Diagnostics, Inc.

- FORM S-1/A

As filed with the Securities and Exchange Commission on June 9, 2017 Registration No.

Underwriting Agreement

EXHIBIT 1.1 UNDERWRITING AGREEMENT among CO-DIAGNOSTICS, INC. and WALLACHBETH Capital, LLC and NETWORK 1 FINANCIAL SECURITIES, INC., as Representatives of the Several Underwriters 1 CO-DIAGNOSTICS, INC. UNDERWRITING AGREEMENT New York, New York [?], 2017 WallachBeth Capital, LLC Network 1 Financial Securities, Inc. As Representatives of the several Underwriters named on Schedule 1 attached hereto

Form Second Amendment to 12% Revolving Line of Credit Promissory Note Due 2017 between Co-Diagnostics, Inc. and CoDiagnostics, Ltd., Pine Valley Investments, LLC, Clavo Rico Incorporated, Legends Capital Group, LLC, and Hamilton Mining Resources, Inc. (4)

EXHIBIT 10.13.7 SECOND AMENDMENT TO 12% REVOLVING LINE OF CREDIT PROMISSOPRY NOTE DUE 2017 OF CO-DIAGNOSTICS, INC. Original Principal Amount: $ Original Issuance Date: Whereas, THIS AMENDMENT TO THE 12% PROMISSORY NOTE dated , as amended (the ?Note?) is entered into, by and between Co-Diagnostics, Inc., a Utah corporation (the ?Company?) and , a (?Holder?); Now therefore, the Note is hereby amende

Form of Indemnification Agreement

EXHIBIT 10.13.8 DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT This Director and Officer Indemnification Agreement, dated as of (this ?Agreement?), is made by and between Co-Diagnostics, Inc., a Utah corporation (the ?Company?), and (the ?Indemnitee?). RECITALS: A. Utah Revised Business Corporation Act provides that the business and affairs of a corporation shall be managed by or under the directi

-

May 24, 2017 Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, DC 20549 Attn: Amanda Ravitz Re: Co-Diagnostics, Inc.

- FORM S-1/A

As filed with the Securities and Exchange Commission on May 24 , 2017 Registration No.

Mutual Rescission Agreement of the Stock Purchase Agreement, dated September 22, 2016, and the License Agreement, dated October 13, 2016, between Co-Diagnostics, Robert Salna, and Ted Murphy, dated March 30, 2017. (3)

EXHIBIT 10.20 MUTUAL RESCISSION AGREEMENT THIS MUTUAL RESCISSION AGREEMENT (?Agreement?) is entered into on the dates set forth below but effective as of September 22, 2016 (the ?Effective Date?), by and between Co-Diagnostics, Inc., a Utah corporation (the ?Company?), and Robert Salna and Ted Murphy, individuals with an address located at 64 Industrial Road, Richmond Hill, Ontario L4C 2Y1, Canada

Amended Exclusive License Agreement between Co-Diagnostics, Brent Satterfield, and DNA Logix, Inc., dated January 1, 2017

EXHIBIT 10.17 AMENDED EXCLUSIVE LICENSE AGREEMENT This Amendment to Exclusive License Agreement is made and entered into effective January 1, 2017 by and between Co-Diagnostics, Inc. (?Licensee?) and Brent Satterfield (?Licensor?) to that certain license agreement (?License Agreement?) dated April 18, 2014 between Licensee and DNA Logix, Inc. , which as been assigned to Licensor. WHEREAS, the part

Amendment to 12% Revolving Line of Credit Promissory Note, March 1, 2016, between Co-Diagnostics and Legends Capital Group, LLC for $100,000, dated September 14, 2016. (3)

EXHIBIT 10.13.4 AMENDMENT TO 12% REVOLVING LINE OF CREDIT PROMISSOPRY NOTE DUE 2016 OF CO-DIAGNOSTICS, INC. Original Principal Amount: $100,000 Original Issuance Date: March 1, 2016 Whereas, THIS AMENDMENT TO THE 12% PROMISSORY NOTE dated March 1, 2016 as amended (the ?Note?) is entered into, by and between Co-Diagnostics, Inc., a Utah corporation (the ?Company?) and Legends Capital Group, LLC (?H

Form Revolving Line of Credit Promissory Note between Co-Diagnostics and Turks and Caicos Limited Company, Pine Valley Investments, LLC, Clavo Rico Incorporated, Legends Capital Group, LLC, Hamilton Mining Resources, Inc., and Machan 1988 Property Trust. (3)

EXHIBIT 10.13 REVOLVING LINE OF CREDIT PROMISSORY NOTE Amount: $ Date: , 2016 WHEREAS, the Borrower desires to borrow funds from the Lender from time to time and the parties desire to enter into a note which provides for advances from time to time on an unsecured basis. THEREFOR, FOR VALUE RECEIVED, CO-DIAGNOSTICS, INC. a Utah corporation, (referred to as the "Borrower") promises to pay to MACHAN

Shareholders’ Agreement between Co-Diagnostics and Synbiotics Limited, dated January 27, 2017

EXHIBIT 10.16 SHAREHOLDERS? AGREEMENT This Shareholders? Agreement (hereinafter, the ?Agreement?) is made and entered into this 27th January of 2017. (the ?Effective Date?) BY AND BETWEEN Synbiotics Limited, a company incorporated and registered under the Laws of India under the provisions of Companies Act, 1956, having its registered office at Sarabhai Campus, Gorwa Road, Vadodara ? 390 023 (here

Subscription Agreement between Co-Diagnostics and Co-Diagnostics, Ltd. for 454,545 shares of Co-Diagnostic’s common stock, dated April 20, 2013 (3)

EXHIBIT 10.10

Amendment to 12% Revolving Line of Credit Promissory Note, February 22, 2016, between Co-Diagnostics and Clavo Rico Incorporated for $10,000, dated September 14, 2016. (3)

EXHIBIT 10.13.3 AMENDMENT TO 12% PROMISSOPRY NOTE DUE 2016 OF CO-DIAGNOSTICS, INC. Original Principal Amount: $10,000 Original Issuance Date: February 22, 2016 Whereas, THIS AMENDMENT TO THE 12% PROMISSORY NOTE dated February 22, 2016, as amended (the ?Note?) is entered into, by and between Co-Diagnostics, Inc., a Utah corporation (the ?Company?) and Clavo Rico Incorporated, a Utah corporation (?H

Amendment to 12% Revolving Line of Credit Promissory Note, May 15, 2016, between Co-Diagnostics and Hamilton Mining Resources, Inc. for $75,000, dated September 14, 2016. (3)

EXHIBIT 10.13.5 AMENDMENT TO 12% REVOLVING LINE OF CREDIT PROMISSOPRY NOTE DUE 2016 OF CO-DIAGNOSTICS, INC. Original Principal Amount: $75,000 Original Issuance Date: May 15, 2016 Whereas, THIS AMENDMENT TO THE 12% PROMISSORY NOTE dated May 15, 2016, as amended (the ?Note?) is entered into, by and between Co-Diagnostics, Inc., a Utah corporation (the ?Company?) and Hamilton Mining Resources, Inc.,

Stock Purchase Agreement between Co-Diagnostics and Ted Murphy for 1,800,000 shares of Watermark Group, Inc.’s common stock, dated September 22, 2016. (3)

EXHIBIT 10.18 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (?Agreement?) is made and entered into this day of September, 2016, by and between Ted Murphy with an address located at 64 Industrial road, Richmond Hill, Ontario L4C 2Y1 (?Seller?) and Co-Diagnostics, Inc., a Utah corporation, with an address located at 4049 S. Highland Drive, Salt Lake City, Utah 84124. WHEREAS, Seller is the

Amendment to 12% Revolving Line of Credit Promissory Note, dated August 1, 2015, between Co-Diagnostics and Co-Diagnostics, Ltd., for $750,000, dated September 14, 2016. (3)

EXHIBIT 10.13.1 AMENDMENT TO 12% REVOLVING LINE OF CREDIT PROIVIISSOPRY NOTE DUE 2016 OF CO-DIAGNOSTICS, INC. Original Principal Amount: $750,000 Original Issuance Date: August 1, 2015 Whereas, THIS AMENDMENT TO THE 12% PROMlSSORY NOTE dated August 1, 2015, as amended (the ''Note") is entered into, by and between Co-Diagnostics, Inc., a Utah corporation (the "Company') and Co-Diagnostics, Ltd, a T

Amendment to 12% Revolving Line of Credit Promissory Note, May 30, 2016, between Co-Diagnostics and Machan 1988 Property Trust for $50,000, dated September 14, 2016. (3)

EXHIBIT 10.13.6 AMENDMENT TO 12% REVOLVING LINE OF CREDIT PROMISSORY NOTE DUE 2016 OF CO-DIAGNOSTICS, INC. Original Principal Amount: $50,000 Original Issuance Date: May 30, 2016 Whereas, THIS AMENDMENT TO THE 12% PROMISSORY NOTE dated May 30, 2016, as amended (the ?Note?) is entered into, by and between Co-Diagnostics, Inc., a Utah corporation (the ?Company?) and Machan 1988 Property Trust (?Hold

Subscription Agreement between Co-Diagnostics and Prosperity Investments for $100,000, dated June 2014. (3)

EXHIBIT 10.11 CO-DIAGNOSTICS, INC. PROSPERITY INVESTMENTS SUBSCRIPTION AGREEMENT 1. SUBSCRIPTION. The undersigned hereby applies to subscribe to purchase 500,000 shares of the common stock of Co-Diagnostics, Inc., a Utah corporation (the ?Corporation?), $.001 par value per share (the ?Shares?), in consideration of the payment to the Corporation of the sum of $100,000. THE UNDERSIGNED ACKNOWLEDGES

Amendment to 12% Revolving Line of Credit Promissory Note, December 30, 2015, between Co-Diagnostics and Pine Valley Investments, LLC for $100,000, dated September 14, 2016. (3)

EXHIBIT 10.13.2 AMENDMENT TO 12% REVOLVING LINE OF CREDIT PROMISSOPRY NOTE DUE 2016 OF CO-DIAGNOSTICS, INC. Original Principal Amount: $100,000 Original Issuance Date: December 30, 2015 Whereas, THIS AMENDMENT TO THE 12% PROMISSORY NOTE dated December 30, 2015, as amended (the ?Note?) is entered into, by and between Co-Diagnostics, Inc., a Utah corporation (the ?Company?) and Pine Valley Investmen